Kodiak Sciences, Inc. (KOD)

Kodiak Sciences' stock experienced several events in the past six months. In December 2025, the company closed a public offering of common stock totaling $184 million. In January 2026, UBS Group upgraded Kodiak Sciences to a "strong-buy" rating. A director, Bros. Advisors LP Baker, purchased 2,608,696 shares of Kodiak Sciences stock in December 2025 for approximately $60 million. The share price of Kodiak Sciences Inc. increased by 254.93% between January 13, 2025, and January 9, 2026. The company reported a loss of ($1.16) EPS for Q3 2025, missing consensus estimates.

Analysis of Kodiak Sciences Inc. stock over the past six years suggests a seasonal pattern. A "Buy Date of August 18 and a Sell Date of December 26" has historically resulted in a geometric average return of 96% above the S&P 500 Total Return Index. The seasonal strength for KOD is inline with the broader Healthcare sector, which typically runs from April 25 to December 4.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for retinal diseases. The company aims to create durable treatments for conditions like wet AMD, DME, RVO, and DR. Its major product candidates include Tarcocimab tedromer (KSI-301), KSI-501, and KSI-101, developed using its ABC Platform®.

Kodiak Sciences Inc. is based in Palo Alto, California, United States. The company aims to expand its presence in international markets, but specific operational locations outside the U.S. are not detailed.

Kodiak Sciences' brand reputation appears to be moderately positive, particularly within the investment community. The company has received a consensus rating of "Moderate Buy" from analysts. Kodiak Sciences scored higher than 38% of companies evaluated by MarketBeat. Positive developments in its clinical trials have helped to reinstate faith in the company's potential to treat retinal diseases.

Kodiak Sciences Inc. has a significant portion of its stock owned by institutional investors and hedge funds. As of September 2025, Kodiak Sciences had 262 institutional owners holding a total of 47,446,733 shares. Victor Perlroth, the CEO, holds a significant stake, with approximately 5.1% to 6.61% of the shares. Baker Bros. Advisors LP is also identified as the largest individual shareholder, owning 18.36 million shares, representing 34.61% of the company. Insiders collectively own shares valued at approximately $46 million. The general public holds about a 10% stake.